<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391351</url>
  </required_header>
  <id_info>
    <org_study_id>miRSa</org_study_id>
    <nct_id>NCT01391351</nct_id>
  </id_info>
  <brief_title>Search for Predictors of Therapeutic Response in Ovarian Carcinoma</brief_title>
  <acronym>miRSa</acronym>
  <official_title>Search for Predictors of Therapeutic Response in Patients With Carcinoma of the Ovary, the Fallopian Tube or Peritoneal Serous-type Advanced</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to search for predictors of response to chemotherapy in patients with ovarian
      carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will
      define the comparative profiles of miRNA expression of serum polymorphisms and determine
      differential in 2 patient populations (with or without recurrence 6 months after completion
      of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification
      of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the
      metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be
      studied during the first course in response to chemotherapy. Indeed, the miRNA profile of
      serum may be different at baseline among the 2 types of populations (or non-recurrence at 6
      months).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>search for predictors of response to chemotherapy</measure>
    <time_frame>12 months after beginning treatment</time_frame>
    <description>the search for predictors of response to chemotherapy in patients with carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced by using (i) the miRNA profile of serum before treatment with chemotherapy and (ii) the identification of polymorphisms or SNPs (Single Nucleotide polymorphism) in particular genes involved in the metabolism of chemotherapy agents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>profiling miRNA expression</measure>
    <time_frame>1 month</time_frame>
    <description>- Characterization of the response to treatment with profiling miRNA expression after the first course of chemotherapy in patients with carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>study of changes in serum miRNA expression</measure>
    <time_frame>6 months</time_frame>
    <description>- The study of changes in serum miRNA expression identified as predictive of tumor response during chemotherapy treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Carcinoma of the Ovary</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Serous-type Advanced Stage</condition>
  <arm_group>
    <arm_group_label>Taxol and carboplatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood samples in patients receiving Taxol and carboplatin chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxol, carboplatin and avastin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>blood samples in patients receiving Taxol and carboplatin chemotherapy :
On Day 1 of the first course of chemotherapy
On Day 1 of the second course of chemotherapy
Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
At the end of chemotherapy</description>
    <arm_group_label>Taxol and carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:
On Day 1 of the first course of chemotherapy
On Day 1 of the second course of chemotherapy
Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
At the end of chemotherapy</description>
    <arm_group_label>Taxol, carboplatin and avastin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cancer of the ovary, peritoneum or of the fallopian tube

          -  Stage III or IV

          -  Cancer of serous histology

          -  Patients of any chemotherapy naive

          -  Patients should receive treatment with chemotherapy for first line by Taxol-
             Carboplatin. Avastin is authorized in concomitant.

          -  An initial surgery or through authorized

          -  Patients who signed informed consent

          -  Patients over the age of 18 years

        Exclusion Criteria:

          -  Patients being treated for another cancer chemotherapy and / or hormone therapy

          -  Patients receiving other chemotherapy Taxol-carboplatin associated or not to avastin

          -  Patients under guardianship

          -  Previous history of pelvic radiotherapy

          -  History of malignancy blood
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY-LOBBEDEZ, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie KRIEGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Réné Gauducheau</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar LAMBRET</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de la loire</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut CURIE</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage</keyword>
  <keyword>chemotherapy with Taxol and Carboplatin</keyword>
  <keyword>predictors of therapeutic response</keyword>
  <keyword>serum miRNA</keyword>
  <keyword>identification of polymorphisms or SNPs (Single Nucleotide Polymorphism)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

